Efficacy and Safety of Newly Installed Spot Scanning Proton Beam Therapy for Prostate Cancer

Overview

Journal In Vivo

Specialty Oncology

Date 2025 Feb 26

PMID 40011002

Authors

Sachika Shiraishi

Yukiyasu Horikawa

Ryota Umeda

Kazuki Matsumoto

Akihiro Yamano

Masashi Yamanaka

Takahiro Shimo

Taro Murai

Ichiro Miura

Koichi Tokuuye

Affiliations

Soon will be listed here.

Abstract

Background/aim: This study aimed to analyse retrospectively the initial treatment outcomes and associated toxicities of a spot scanning proton beam therapy for prostate cancer at the Shonan-Kamakura General Hospital.

Patients And Methods: A laterally opposing single-field uniform dose of spot-scanning proton beam was used. The doses were determined to be 60 Gy in 20 fractions for low-risk prostate cancer and 63 Gy in 21 fractions for intermediate- and high-risk prostate cancers. Genitourinary (GU) and gastrointestinal (GI) toxicities were also evaluated. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Results: A total of 135 patients were treated over two years, 51 of whom underwent hydrogel spacer insertion. During the limited observation period, no patient experienced a recurrence. Grade 2 GU toxicities were observed in 17 patients, whereas grade 1 or greater GI toxicities were observed in seven patients. None of the patients in whom a hydrogel spacer was inserted experienced grade 1 or higher GI toxicity.

Conclusion: Proton beam therapy is safe for the treatment of prostate cancer. The insertion of a gold marker and hydrogel spacer led to a reduction in the rectal radiation dose and GI toxicity.

References

Moteabbed M, Trofimov A, Sharp G, Wang Y, Zietman A, Efstathiou J . A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016; 95(1):444-453. PMC: 4834287. DOI: 10.1016/j.ijrobp.2015.12.366. View

Takagi M, Demizu Y, Fujii O, Terashima K, Niwa Y, Daimon T . Proton Therapy for Localized Prostate Cancer: Long-Term Results From a Single-Center Experience. Int J Radiat Oncol Biol Phys. 2020; 109(4):964-974. DOI: 10.1016/j.ijrobp.2020.11.007. View

Catalona W . Prostate Cancer Screening. Med Clin North Am. 2018; 102(2):199-214. PMC: 5935113. DOI: 10.1016/j.mcna.2017.11.001. View

Sheets N, Goldin G, Meyer A, Wu Y, Chang Y, Sturmer T . Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307(15):1611-20. PMC: 3702170. DOI: 10.1001/jama.2012.460. View

Kirk M, Tang S, Zhai H, Vapiwala N, Deville C, James P . Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Pract Radiat Oncol. 2014; 5(2):99-105. DOI: 10.1016/j.prro.2014.05.008. View

Pisani C, Galla A, Loi G, Beldi D, Krengli M . Urinary toxicity in patients treated with radical EBRT for prostate cancer: Analysis of predictive factors in an historical series. Bull Cancer. 2022; 109(7-8):826-833. DOI: 10.1016/j.bulcan.2022.03.011. View

Slater J, Rossi Jr C, Yonemoto L, Bush D, Jabola B, Levy R . Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004; 59(2):348-52. DOI: 10.1016/j.ijrobp.2003.10.011. View

Shimizu S, Miyamoto N, Matsuura T, Fujii Y, Umezawa M, Umegaki K . A proton beam therapy system dedicated to spot-scanning increases accuracy with moving tumors by real-time imaging and gating and reduces equipment size. PLoS One. 2014; 9(4):e94971. PMC: 3991640. DOI: 10.1371/journal.pone.0094971. View

Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D . Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015; 92(5):971-977. DOI: 10.1016/j.ijrobp.2015.04.030. View

10.

Shipley W, Verhey L, Munzenrider J, Suit H, Urie M, McManus P . Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995; 32(1):3-12. DOI: 10.1016/0360-3016(95)00063-5. View

11.

Miller L, Efstathiou J, Bhattacharyya S, Payne H, Woodward E, Pinkawa M . Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020; 3(6):e208221. PMC: 7301230. DOI: 10.1001/jamanetworkopen.2020.8221. View

12.

David R, Buckby A, Kahokehr A, Lee J, Watson D, Leung J . Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022; 26(1):8-15. PMC: 10023565. DOI: 10.1038/s41391-022-00520-x. View

13.

Harvey M, Ong W, Chao M, Udovicich C, McBride S, Bolton D . Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer. BJU Int. 2022; 131(3):280-287. PMC: 9734283. DOI: 10.1111/bju.15821. View

14.

Donovan J, Hamdy F, Lane J, Mason M, Metcalfe C, Walsh E . Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016; 375(15):1425-1437. PMC: 5134995. DOI: 10.1056/NEJMoa1606221. View

15.

WILSON R . Radiological use of fast protons. Radiology. 2010; 47(5):487-91. DOI: 10.1148/47.5.487. View

16.

Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C . Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. J Clin Oncol. 2024; 42(16):1943-1952. DOI: 10.1200/JCO.23.01604. View

17.

Kuban D, Tucker S, Dong L, Starkschall G, Huang E, Cheung M . Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 70(1):67-74. DOI: 10.1016/j.ijrobp.2007.06.054. View

18.

Bao A, Barsky A, Both S, Christodouleas J, Deville Jr C, Tochner Z . Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. Int J Part Ther. 2023; 10(1):1-12. PMC: 10563661. DOI: 10.14338/IJPT-23-00002.1. View

19.

Paganetti H . Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol. 2012; 57(11):R99-117. PMC: 3374500. DOI: 10.1088/0031-9155/57/11/R99. View

20.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D . Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17(8):1047-1060. PMC: 4961874. DOI: 10.1016/S1470-2045(16)30102-4. View